Compare Amphastar Pharmaceuticals Inc (AMPH) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Texas Instruments Incorporated — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Texas Instruments Incorporated trades at $306.71 (market cap $283.46B). The key difference: Texas Instruments Incorporated is far larger — about 343.1× Amphastar Pharmaceuticals Inc's market cap, and Texas Instruments Incorporated pays a 1.82% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | TXN | |
|---|---|---|
Market Cap | $826.08M | $283.46B |
Sector | Health | Technology |
52-Week High | $30.81 | $332.35 |
52-Week Low | $16.87 | $153.33 |
Enterprise Value | $1.22B | $292.40B |
Dividend Yield | — | 1.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Texas Instruments (TXN) trades at $311.51, up 0.94% today, showing strong technical momentum with a bullish moving average signal. The company reported mixed Q1 2026 earnings, beating expectations with $1.68 EPS versus $1.36 expected, while Q3 and Q4 2025 missed. Recent CFO transition to Julie Knecht signals stable leadership. Revenue grew to $17.68B in 2025 from $15.6B in 2024, with net income margin at 29.11%.
Outlook remains positive with 65 analysts showing 48% buy rating and $310.95 consensus target. Key risks include high valuation multiples (P/E 53.24) and rising debt-to-asset ratio (40.61% in 2025). AI-driven data center demand presents growth opportunity, but competition and macroeconomic pressures warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
